LUCD vs. BVS, AVNS, ZIMV, BFLY, KIDS, TMCI, SMLR, CBLL, DCTH, and RXST
Should you be buying Lucid Diagnostics stock or one of its competitors? The main competitors of Lucid Diagnostics include Bioventus (BVS), AVANOS MEDICAL (AVNS), ZimVie (ZIMV), Butterfly Network (BFLY), OrthoPediatrics (KIDS), Treace Medical Concepts (TMCI), Semler Scientific (SMLR), CeriBell (CBLL), Delcath Systems (DCTH), and RxSight (RXST). These companies are all part of the "medical equipment" industry.
Lucid Diagnostics vs. Its Competitors
Bioventus (NYSE:BVS) and Lucid Diagnostics (NASDAQ:LUCD) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk, media sentiment and dividends.
Bioventus has a net margin of -7.11% compared to Lucid Diagnostics' net margin of -1,476.35%. Bioventus' return on equity of 15.61% beat Lucid Diagnostics' return on equity.
Lucid Diagnostics has lower revenue, but higher earnings than Bioventus.
Bioventus has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500. Comparatively, Lucid Diagnostics has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500.
62.9% of Bioventus shares are held by institutional investors. Comparatively, 74.0% of Lucid Diagnostics shares are held by institutional investors. 33.0% of Bioventus shares are held by insiders. Comparatively, 6.8% of Lucid Diagnostics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
In the previous week, Lucid Diagnostics had 5 more articles in the media than Bioventus. MarketBeat recorded 6 mentions for Lucid Diagnostics and 1 mentions for Bioventus. Bioventus' average media sentiment score of 0.93 beat Lucid Diagnostics' score of 0.36 indicating that Bioventus is being referred to more favorably in the media.
Bioventus currently has a consensus price target of $13.75, indicating a potential upside of 106.77%. Lucid Diagnostics has a consensus price target of $3.70, indicating a potential upside of 252.38%. Given Lucid Diagnostics' higher probable upside, analysts plainly believe Lucid Diagnostics is more favorable than Bioventus.
Summary
Lucid Diagnostics beats Bioventus on 8 of the 15 factors compared between the two stocks.
Get Lucid Diagnostics News Delivered to You Automatically
Sign up to receive the latest news and ratings for LUCD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding LUCD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lucid Diagnostics Competitors List
Related Companies and Tools
This page (NASDAQ:LUCD) was last updated on 10/8/2025 by MarketBeat.com Staff
